Anders Björk

Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

Per Björk, Anders Björk, Thomas Vogl et al. · PLoS Biology · 2009 · 359 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich et al. · Journal of Clinical Oncology · 2011 · 208 citations

Medicine, Oncology, Pharmacology +11

Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship

Stig Jönsson, Gunnar Andersson, Tomas Fex et al. · Journal of Medicinal Chemistry · 2004 · 157 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

Anders Olsson, Anders Björk, Johan Vallon‐Christersson et al. · Molecular Cancer · 2010 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

John T. Isaacs, David Z. Qian, Susan L. Dalrymple et al. · The Prostate · 2006 · 87 citations

Medicine, Oncology, Pharmacology +13